H.C. Wainwright lowered the firm’s price target on PMV Pharmaceuticals to $5 from $29 and keeps a Buy rating on the shares after the company presented updated Phase 1/2 results for PC14586. The analyst sees opportunities to combine PC14586 with a variety of additional agents, including anti-PD1. However, the firm sees a lower probability for tumor-agnostic monotherapy deployment of PC1458.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on PMVP:
- PMV Pharmaceuticals Updated PC14586 Phase 1 Data Demonstrated Anti-Tumor Activity Across Multiple Solid Tumor Types With a TP53 Y220C Mutation
- PMV Pharmaceuticals’ PC14586 Phase 1 data demonstrates anti-tumor activity
- PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics and Host a KOL Webinar
- PMV Pharmaceuticals to Present Updated Phase 1 Data on PC14586 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
